Assure Holdings Corp. (the “Company” or “Assure”) (TSXV: IOM; OTCQB: ARHH), a provider of intraoperative neuromonitoring services (IONM), is pleased to announce that effective February 24, 2021, it has signed a Term Sheet (“Term Sheet”) to acquire (the “Acquisition”) Sentry Neuromonitoring, LLC (“Sentry”), one of the largest IONM service providers in Texas, for a purchase price of $3,500,000. The purchase price to be paid is $1,225,000 in cash and $2,275,000 in Assure common stock, subject to escrow, TSX Venture Exchange and other requirements.
Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, has completed its previously announced acquisition of molecular oncology leader Biotheranostics, Inc. for approximately $230 million. Biotheranostics develops and markets two highly differentiated molecular diagnostic tests for breast and metastatic cancers – Breast Cancer Index™ (BCI) and CancerTYPE ID® (CTID).
Butterfly Network, Inc. (“Butterfly” or the “Company”) (NYSE: BFLY), an innovative digital health company that is working to democratize medical imaging and contribute to the aspiration of global health equity, today announced that it has completed its business combination with Longview Acquisition Corp. (NYSE: LGVW.U, LGVW, LGVW WS) (“Longview”), a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management, LLC (“Glenview”).
GenMark Diagnostics Inc. is exploring a sale after the U.S. firm was approached by potential buyers, according to people familiar with the matter. GenMark is working with a financial adviser as it fields interest from other medical diagnostics companies, the people said, asking not to be identified because the deliberations are private. GenMark competes with companies including Hologic Inc. and Quidel Corp. in the booming medical testing industry. It makes molecular diagnostic equipment to help detect infectious diseases including respiratory pathogens, and for blood culture identification.
Longview Acquisition Corp. (NYSE: LGVW.U, LGVW, LGVW WS) , a special purpose acquisition company sponsored by an affiliate of Glenview Capital Management, LLC, announced today that its stockholders voted to approve the proposed business combination with Butterfly Network, Inc. with nearly 100% of the shares of Longview voted at the Special Meeting in favor of the business combination proposal. Founded by Dr. Jonathan Rothberg in 2011, Butterfly has created the world’s first handheld, single-probe whole-body ultrasound system, Butterfly iQ.
Apex Physics Partners (APP), a leading medical physics business services support organization, is proud to announce a new partnership with Advanced Medical Physics (AMP), a leader in diagnostic medical physics services in Indiana. The partnership with Advanced Medical Physics represents the seventh transaction for Apex Physics Partners since inception and the fourth transaction in less than two years of partnership with Blue Sea Capital.
Quidel Corp., the U.S. diagnostics firm, is weighing a combination with Qiagen NV in another sign of ongoing appetite for dealmaking in the medical equipment industry, people with knowledge of the matter said. Quidel, which makes several types of coronavirus tests, has made a preliminary approach to Qiagen to gauge interest in a potential deal, the people said, asking not to be identified discussing confidential information. Deliberations are at an early stage, and there’s no certainty they will result in a deal, the people said.
HORIBA, Ltd. (Headquarters in Kyoto, Japan, referred to as HORIBA) and HORIBA Instruments (Headquarters in Irvine, California) announced Tuesday that it has acquired MedTest Holdings, Inc. (Headquarters in Canton, MI, USA, composed of MedTest Dx, Inc., Pointe Scientific, Inc., Clinitox Diagnostix, Inc., and Medical Laboratory Solutions, Inc.). The acquisition will combine the complimentary innovative technology offerings of the HORIBA Medical segment (referred to as HORIBA Medical) with MedTest Dx technology, Clinitox, and Pointe Scientific’s R&D and manufacturing capabilities, with particular expertise in FDA 510K and CLIA clearances, to address the multidisciplinary requirements of IVD1 testing customers.
FogChain Corp. (CSE: FOG.X) (OTCB: FOGCF) (FRA: MUU3) (the “Company” or “FogChain”) is pleased to announce, further to its news release dated January 13, 2021, the Company has entered into a merger agreement and plan of reorganization (the “Definitive Agreement”) with Avisa Pharma Inc. (“Avisa”) and FogChain USA Inc., a wholly-owned subsidiary of FogChain. Avisa has developed a quantitative, point–of–care diagnostic breath test known as the Avisa BreathTest (“ABT”) for rapidly detecting bacterial pneumonia and pulmonary infections in approximately 10 minutes.
Veracyte, Inc. (Nasdaq: VCYT) and Decipher Biosciences, Inc., a commercial-stage precision oncology company focused on urologic cancers, today announced they have entered into a definitive agreement through which Veracyte will acquire Decipher, further solidifying Veracyte’s global leadership in the genomic cancer diagnostics market while accelerating revenue growth.
What We Do
Who We Are
How We Work
Who We Help
Get In Touch
Connect With Us
Subscribe to Our Daily Note
We publish a Daily Note that aggregates M&A activity, notable developments, regulatory changes, and conferences we deem to be of interest to our partners. It is a quick afternoon read and an easy way to keep your finger on the pulse of the healthcare space. Please fill in your name and email address below if you wish to subscribe.